Phase I Dose-Escalation Trial Of Cd19/Cd20 Bispecific Chimeric Antigen Receptor (Car) T-Cells For The Treatment Of Relapsed Or Refractory B-Cell Lymphomas And Chronic Lymphocytic Leukemia
BLOOD(2020)
摘要
Background:
更多查看译文
关键词
chronic lymphocytic leukemia,cd19/cd20,dose-escalation,t-cells,b-cell
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要